Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another ...
The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...
Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...
Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead ...
Bill Grossman is leaving Arcus Biosciences to take up a position at Gilead, putting him in charge of the Big Pharma's collaboration with his former employers. Grossman is currently chief medical ...
Gilead Sciences (GILD 2.18%) and Arcus Biosciences (RCUS 4.04%) have signed a 10-year agreement to co-develop and co-commercialize the next-generation cancer therapeutics in Arcus' pipeline. The ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Zacks Investment Research on MSN
Arcus Biosciences (RCUS) moves 7.8% higher: Will this strength last?
Arcus Biosciences, Inc. (RCUS) shares ended the last trading session 7.8% higher at $24.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results